Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (B-SCR-MM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01408225|
Recruitment Status : Recruiting
First Posted : August 3, 2011
Last Update Posted : January 13, 2020
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:
- Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live.
- Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups.
- Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.
|Condition or disease||Intervention/treatment|
|Plasma Cell Dyscrasias Monoclonal Gammopathy of Undetermined Significance AL Amyloidosis Multiple Myeloma||Procedure: tissue banking|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||5000 participants|
|Target Follow-Up Duration:||10 Years|
|Official Title:||Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis|
|Actual Study Start Date :||March 17, 2011|
|Estimated Primary Completion Date :||March 2050|
|Estimated Study Completion Date :||March 2050|
- Procedure: tissue banking
tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
- Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohio [ Time Frame: up to 3 years ]
- Surveillance [ Time Frame: up to 3 years ]Establish a database of myeloma patients diagnosed or living in the state of Ohio to track myeloma disease course, patient reported outcomes, morbidity, and patient survival.
- Contact [ Time Frame: up to 3 years ]Provide two-way communication with patients by providing information regarding multiple myeloma, local support groups, and standard of care procedures through active contact procedures
- Research [ Time Frame: up to 3 years ]Offer patients, and occasionally spouses and family members, the opportunity to participate in tissue banking, observational, patient reported outcomes, and therapeutic clinical trials for their plasma cell dyscrasia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01408225
|Contact: The Ohio State University Comprehensive Cancer Center||1-800-293-5066||OSUCCCClinicaltrials@osumc.edu|
|United States, Ohio|
|Ohio State University Medical Center||Recruiting|
|Columbus, Ohio, United States, 43210|
|Contact: Nita Williams 614-293-3818 firstname.lastname@example.org|
|Principal Investigator: Ashley Rosko, MD|
|Principal Investigator:||Ashley Rosko, MD||Ohio State University|